{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-064577","form_type":"8-K","ticker":"RLMD","cik":"0001553643","company_name":"RELMADA THERAPEUTICS, INC.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.279045+00:00","generated_at":"2026-06-12T01:49:58.655287+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Relmada Q2 net loss narrows; Phase 3 MDD trials on track for 2024","bullets":["Net loss $25.3M ($0.84/share) vs $39.9M ($1.33) in Q2 2022; R&D expense down to $13.7M from $30.9M.","Cash and short-term investments $118.5M at June 30; company says sufficiently funded for Phase 3 readouts in 2024.","Phase 3 Reliance II (302) enrollment ongoing; Relight (304) screening started; both expected to complete in 2024.","One-year open-label safety study (Reliance-OLS) completed; data expected later in the current quarter.","Human abuse potential data for REL-1017 published in peer-reviewed Translational Psychiatry."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-064577","json":"https://secwatch.observer/filing/0001213900-23-064577.json","markdown":"https://secwatch.observer/filing/0001213900-23-064577.md","text":"https://secwatch.observer/filing/0001213900-23-064577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/0001213900-23-064577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/ea183083-8k_relmada.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:49:58.655287+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61822cf1b5eef53a276a18ca2ac4355b90b1003d","claim":"RELMADA THERAPEUTICS, INC. reported six months ended June 30, 2023 results: net income $51.6 million, EPS $1.72 per share.","evidence_excerpt":"Net loss for the six months ended June 30, 2023 and 2022 was $51.6 million and $79.7 million, respectively. The Company had a net loss of $1.72 and $2.73 per share for the six months ended June 30, 2023 and 2022, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/0001213900-23-064577-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"six months ended June 30, 2023"},{"label":"Net income","value":"$51.6 million"},{"label":"EPS","value":"$1.72 per share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"7b78aca9972eeb2b3c7f8ffdbb0975d116042290","claim":"RELMADA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: net income $25.3 million, or $0.84 per basic and diluted share, EPS $0.84 per basic and diluted share.","evidence_excerpt":"Net loss for the three months ended June 30, 2023, was $25.3 million, or $0.84 per basic and diluted share, compared with a net loss of $39.9 million, or $1.33 per basic and diluted share, for the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1553643/000121390023064577/0001213900-23-064577-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"$25.3 million, or $0.84 per basic and diluted share"},{"label":"EPS","value":"$0.84 per basic and diluted share"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}